Salim S. Abdool Karim

Among 889 women, HIV incidence 5.6 vs 9.1 per 100 women-years (IRR 0.61; P=0.017), an estimated 39% reduction; 54% among high adherers; 51% reduction in HSV-2. A later trial, FACTS 001 (over 2,000 women; results presented Feb 2015), found no protective effect: 61 infections in the tenofovir-gel arm vs 62 on placebo, with low consistent gel use reported

Role

Co-principal investigator / CAPRISA director

Reported by

CAPRISA 004 figures as reported by Abdool Karim and Baxter (2010); FACTS 001 result as reported by Mail & Guardian (2015)

Sources ^{1 2}

CAPRISA 004 described as proof of concept that antiretroviral drugs can prevent sexually transmitted HIV and HSV-2 in women, and as leading later to pre-exposure prophylaxis (PrEP)

Role

CAPRISA director

Reported by

Columbia University; Lasker Foundation award citation

Sources ^{3 4}

After five years of use in South Africa, annual deaths fell by over 50% (as stated in award release; trial and metric not named)

Role

Researcher (with Quarraisha Abdool Karim)

Reported by

Columbia University news release on Lasker award

Sources ³